Geneva, June 22 -- International Clinical Trials Registry received information related to the study (ChiCTR2600126659) titled 'The safety and efficacy of the steep pulse therapy device in ablation for unresectable hilar and distal bile duct cancers' on June 12.

Study Type: Interventional study

Study Design: Single arm

Primary Sponsor: Beijing Ditan Hospital, Capital Medical University

Condition: Inoperable hilar and distal bile duct cancer

Recruitment Status: Not Recruiting

Phase: N/A

Date of First Enrollment: 2026-06-15

Target Sample Size: Experimental group:10;

Countries of Recruitment: China

To know more, visit https://www.chictr.org.cn/showproj.html?proj=317670

Published by HT Digital Content Services with permission ...